Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial

BACKGROUND: In HER2-positive breast cancer, time elapsed between completion of (neo)adjuvant trastuzumab and diagnosis of metastatic disease (‘trastuzumab-free interval’, TFI) is crucial to choose the optimal first-line treatment. Nevertheless, there is no clear evidence to support its possible prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambertini, Matteo, Agbor-Tarh, Dominique, Metzger-Filho, Otto, Ponde, Noam F, Poggio, Francesca, Hilbers, Florentine S, Korde, Larissa A, Chumsri, Saranya, Werner, Olena, Del Mastro, Lucia, Caparica, Rafael, Moebus, Volker, Moreno-Aspitia, Alvaro, Piccart, Martine J, de Azambuja, Evandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643526/
https://www.ncbi.nlm.nih.gov/pubmed/33154022
http://dx.doi.org/10.1136/esmoopen-2020-000979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643526/
https://www.ncbi.nlm.nih.gov/pubmed/33154022
http://dx.doi.org/10.1136/esmoopen-2020-000979

Ejemplares similares